Pigmentation is one of the most biologically complex visible concerns in aesthetic medicine — and one of the most poorly explained. The standard framing — "sun damage," addressed with a brightening serum — collapses a multi-pathway molecular process into a single cause and a single solution. Neither is sufficient.
Understanding how pigment actually forms, what drives its dysregulation, and why it behaves so differently across individuals and skin types is the prerequisite for a protocol that actually works.
The Melanogenesis Pathway: A Brief Account
Pigmentation begins with the melanocyte — a specialised cell found in the basal layer of the epidermis, at the interface of dermis and skin. Melanocytes synthesise melanin and transfer it to the surrounding keratinocytes, which carry it upward through the layers of the epidermis as the skin renews. The visible pigment you see on the surface is melanin that has been transferred and accumulated in these keratinocytes.
The rate and pattern of that synthesis is controlled by a cascade that begins at the Melanocortin 1 Receptor (MC1R) — a G-protein coupled receptor on the surface of the melanocyte. When stimulated — by Ultraviolet (UV) radiation, by alpha-melanocyte stimulating hormone (α-MSH), or by the paracrine signals from surrounding keratinocytes — MC1R activation triggers a signalling cascade that activates the Melanocyte Inducing Transcription Factor (MITF).
MITF is the master regulator of the melanocyte. When activated, it drives the expression of the enzymes responsible for melanin synthesis — principally tyrosinase, the rate-limiting catalyst of the pathway, and TRP-1 and TRP-2 (tyrosinase-related proteins). Melanin production follows.
This is the normal, functional pathway — the skin's photoprotective response to UV exposure. The problem arises when this pathway becomes dysregulated: chronically overactivated, unevenly distributed, or driven by triggers beyond UV alone.
Why Pigmentation Is Not Simply a Sun Problem
UV is the most well-known trigger of the MC1R-MITF-tyrosinase cascade. But it is not the only one.
Hormonal signalling is a significant independent driver. Oestrogen and progesterone both directly stimulate melanocyte activity — which is why pregnancy, hormonal contraception, and perimenopause consistently produce or worsen pigmentation. This is melasma in its classical form: hormonally driven, patterned on the face in regions of high melanocyte density, and stubbornly resistant to UV-only interventions because the upstream hormonal stimulus persists regardless of sun protection.
Inflammation activates the pathway through a different mechanism. When the skin undergoes injury, infection, or irritation, keratinocytes release prostaglandins and interleukins that stimulate melanocyte activity via the paracrine environment. This produces Post-Inflammatory Hyperpigmentation (PIH) — pigmentation that forms in the wake of a wound, acne lesion, procedure, or inflammatory episode. PIH is particularly significant in Fitzpatrick IV–VI skin, where the melanocyte population is more densely active and more sensitive to inflammatory stimulus.
The Genetic Architecture of Pigmentation Risk
Perhaps the most underappreciated dimension of pigmentation biology is its genetic basis. MC1R polymorphisms — variants in the gene encoding the MC1R receptor — produce functionally different receptor behaviours in different individuals. Some variants reduce receptor sensitivity, producing lighter pigmentation and higher UV sensitivity (characteristic of Fitzpatrick I–II skin). Others produce a constitutively more active receptor, predisposing to darker baseline pigmentation and a more robust melanogenic response to any stimulus.
In populations of African, South Asian, and mixed heritage — which constitute the majority of individuals in a clinical practice in the Western Cape — MC1R polymorphisms are highly prevalent and clinically significant. They mean that two individuals with identical UV exposure and identical skincare behaviour may have dramatically different pigmentation responses. The difference is not behavioural. It is molecular.
A precision protocol that does not account for this genetic architecture is applying a population-level assumption to an individual-level problem.
The Paracrine Environment: What the Dermis Is Saying
The dermis beneath the melanocyte is not a passive backdrop. It is an active signalling environment — and the paracrine signals it generates directly influence melanocyte behaviour.
Dermal fibroblasts, for instance, secrete stem cell factor (SCF) — a melanocyte survival and activation signal. When fibroblast activity increases (as it does in response to UV injury, wound healing, and inflammatory states), SCF secretion increases, and the melanocyte responds by ramping up melanin production. This is one mechanism by which sun exposure produces tanning even when UV is blocked by a topical filter — the inflammatory component of solar radiation (including infrared and visible light) activates fibroblasts, which stimulate melanocytes through the paracrine route.
This is why broad-spectrum photoprotection — including infrared and visible light protection, not just UVA/UVB — is the correct standard for individuals with active melanogenesis dysregulation.
What a Precision Protocol Targets
A precision approach to pigmentation addresses the pathway at multiple points:
At the MC1R level: blocking the upstream stimulus where possible — hormonal regulation, aggressive broad-spectrum photoprotection, anti-inflammatory management.
At the MITF level: tranexamic acid, niacinamide, and kojic acid all influence MITF activity or its downstream targets through different mechanisms, producing additive inhibition when combined correctly.
At the tyrosinase level: arbutin, kojic acid, and vitamin C derivatives directly inhibit tyrosinase activity, reducing the rate of melanin synthesis at the enzymatic step.
At the transfer level: retinoids accelerate keratinocyte turnover, reducing the residence time of melanin in the epidermis and preventing accumulation.
No single active addresses all four levels. No single formula is appropriate for all presentations. And no protocol is complete without genetic and hormonal context — because without those, the intervention is always chasing the visible consequence rather than targeting the mechanism producing it.